Prognostic value of posttreatment [18F] fluorodeoxyglucose uptake of primary non-small cell lung carcinoma treated with radiation therapy with or without chemotherapy: a brief review.
In patients treated with radiation therapy for non-small cell lung carcinoma, positron emission tomography and computed tomography are commonly used to assess response to treatment. Seven rather small single-institution series have documented the ability of posttreatment positron emission tomography to predict local control and survival through measurements of [F] fluorodeoxyglucose uptake. The ability to make prognostic assessments using this information would be a major clinical breakthrough by allowing early alterations in patient management. Here, we review the current literature on the prognostic value of posttreatment [F] fluorodeoxyglucose uptake in patients treated with radiation therapy with or without chemotherapy for non-small cell lung carcinoma.
Kased
Norbert
N
Department of Radiation Oncology, University of California, San Francisco, UCSF Comprehensive Cancer Center, San Francisco, California, USA.
Erasmus
Jeremy J
JJ
Komaki
Ritsuko
R
Cox
James D
JD
D002289:Carcinoma, Non-Small-Cell Lung / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000532:radiotherapy*; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008175:Lung Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000532:radiotherapy*; D011237:Predictive Value of Tests; D011379:Prognosis; D019275:Radiopharmaceuticals; D014055:Tomography, Emission-Computed
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18